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1  | INTRODUC TION
Cirrhosis is characterized by extensive scarring of the liver and can 
develop after many liver diseases. Cirrhosis is associated with medical 
complications including ascites, variceal bleeding and hepatocellular 
carcinoma.1 Cirrhosis accounts for nearly $10 billion in healthcare 
costs in the United States alone and over one million deaths world-
wide in 2015.1,2 While the most common causes of cirrhosis – viral 
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Abstract
Background and Aims: Cirrhosis is characterized by extensive fibrosis of the liver and 
is a major cause of liver-related mortality. Cirrhosis is partially heritable but genetic 
contributions to cirrhosis have not been systemically explored. Here, we carry out 
association analyses with cirrhosis in two large biobanks and determine the effects 
of cirrhosis associated variants on multiple human disease/traits.
Methods: We carried out a genome-wide association analysis of cirrhosis as a diagnosis 
in UK BioBank (UKBB; 1088 cases vs. 407 873 controls) and then tested top-associating 
loci for replication with cirrhosis in a hospital-based cohort from the Michigan Genomics 
Initiative (MGI; 875 cases of cirrhosis vs. 30 346 controls). For replicating variants or var-
iants previously associated with cirrhosis that also affected cirrhosis in UKBB or MGI, 
we determined single nucleotide polymorphism effects on all other diagnoses in UKBB 
(PheWAS), common metabolic traits/diseases and serum/plasma metabolites.
Results: Unbiased genome-wide association study identified variants in/near PNPLA3 
and HFE, and candidate variant analysis identified variants in/near TM6SF2, MBOAT7, 
SERPINA1, HSD17B13, STAT4 and IFNL4 that reproducibly affected cirrhosis. Most 
 affected liver enzyme concentrations and/or aspartate transaminase-to-platelet ratio 
index. PheWAS, metabolic trait and serum/plasma metabolite association analyses 
revealed effects of these variants on lipid, inflammatory and other processes includ-
ing new effects on many human diseases and traits.
Conclusions: We identified eight loci that reproducibly associate with population-
based cirrhosis and define their diverse effects on human diseases and traits.
K E Y W O R D S
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hepatitis, non-alcoholic fatty liver disease (NAFLD) and alcoholic liver 
disease – are environmentally influenced, there is significant variation 
in whether people develop cirrhosis from these diseases.3 Genetics 
contributes to development of cirrhosis with the heritability of liver 
fibrosis and cirrhosis estimated to be about 50%,4 but the genetic de-
terminants of disease have not been systematically explored.
The genetics of cirrhosis has so far been studied within small liver 
disease-specific populations. PNPLA3 and TM6SF2 variants associate 
with increased fibrosis in individuals with NAFLD, alcoholic liver dis-
ease and hepatitis C virus infection.5-7 Variants near MBOAT7 asso-
ciate with alcoholic cirrhosis.6 Variants in or near GCKR, LYPLAL1 and 
HSD17B13 associate with fibrosis in NAFLD patients.8-11 In hepatitis 
C virus-infected patients, rs910049 (in the major histocompatibil-
ity complex region) and single nucleotide polymorphisms (SNPs) in 
MERTK and TULP1 associated with liver fibrosis progression,12,13 as 
does a SNP near PCSK7 in individuals with hereditary hemochroma-
tosis.14 Finally, two monogenic liver diseases are caused by relatively 
common variants: hereditary hemochromatosis, which in 80%-
90% of cases is caused by rs1800562-A (HFE C282Y), and alpha-1 
antitrypsin deficiency, which is caused by mutations in SERPINA1, 
the most common severely deleterious of which is rs28929474-T 
(E342K).15,16 However, penetrance is incomplete for all these vari-
ants, including those in HFE and SERPINA1, and whether these vari-
ants lead to cirrhosis in the general population remains uncertain.
Here, we aim to evaluate the genetics of all-cause cirrhosis in 
the population. We performed a genome-wide association study 
(GWAS) for all cause cirrhosis (1088 cases vs. 407 873 controls) 
in approximately 410 000 individuals of British-Caucasian descent 
from the UK BioBank (UKBB).17 We test top-associating variants and 
previously reported cirrhosis variants for replication with cirrhosis 
(875 cases vs. 30 346 controls) in the Michigan Genomics Initiative 
(MGI).18 We determined the effects of all replicating variants on 
human disease/traits, on metabolic diseases from publically avail-
able GWAS analyses and on serum metabolites.
2  | METHODS
2.1 | Ethics statement
All research in this study was approved by the Institutional Review 
Board of the University of Michigan. UKBB protocols were approved 
by the National Research Ethics Service Committee and all partici-
pants provided written informed consent. Analyses in this project 
were conducted under UKBB Resource Project 18120. All MGI 
participants provided written informed consent approved by the 
University of Michigan Institutional Review Board.
2.2 | Cohorts
The UKBB includes genotypic, clinical and demographic informa-
tion of over 400 000 individuals aged 40-69 at time of recruitment. 
Genotyping and data collection were previously described.19 In brief, 
participants were genotyped on one of two custom arrays: UK BiLEVE 
Axiom Array (n = 50 520) or UKBB Axiom Array (n = 438 692) with 
>95% overlap. SNPs were imputed using the Haplotype Reference 
Consortium. For imputed SNPs, only SNPs with an imputation qual-
ity cut-off of 0.85 were used in analyses. SNPs with minor allele 
count <20 were excluded. After quality control, 18 530 078 SNPs in 
408 961 white-British individuals were included in analysis.
Michigan Genomics Initiative is a prospective cohort with ongoing 
enrolment and at time of analysis included 35 888 subjects. All patients 
undergoing elective surgery at Michigan Medicine (Ann Arbor, MI) are 
potentially eligible for enrolment in this cohort. Participants underwent 
genotyping of peripheral blood on the Illumina HumanCoreExome 
v.12.1 array, a GWAS and exome array consisting of >500 000 SNPs.18 
In addition, full laboratory information and diagnosis codes are avail-
able. Imputation was performed as previously described.20 In brief, 
samples were imputed to Haplotype Reference Consortium (release 
1 for chromosomes 1-22 and 1.1 for X); SNPs were excluded if im-
putation quality was low (r2 < 0.3) or minor allele count was <4. After 
quality control, 30 751 457 imputed SNPs were available.
2.3 | GWAS
This study had three stages (Figure 1). We limited analyses to indi-
viduals of European ancestry as there were not enough individuals 
from other ancestries to carry out powered analyses. Stage 1 was 
a GWAS for cirrhosis as defined by International Classification of 
Diseases (ICD)-10 code K70.2-4, K71.7, or K74.X in UKBB. SNPs 
within 500 kilobases of a lead SNP with lower p value were re-
moved to identify independent signals. In stage 2, independent 
SNPs with P < 5 × 10−6 in UKBB were tested for association with 
cirrhosis in MGI as defined by the presence of an ICD-9 code for 
cirrhosis (571.5, 571.2 and 571.6), ICD-10 code for cirrhosis (K74.X, 
K70.2-4 and K71.7), or for cirrhosis being present in pathology or 
radiology reports using text searching. Text search of radiology 
and pathology reports was performed for the character ‘cirrho’, 
Key points
• Some genes cause cirrhosis, which is scarring of the liver 
that occurs after prolonged injury, but the genetics of 
cirrhosis have not been previously studied in an unbi-
ased manner.
• We identified two genetic mutations that cause cirrhosis 
at genome-wide significance and validated six other mu-
tations previously suggested to affect cirrhosis in small 
studies now in large biobanks.
• We show that these variants affect multiple human dis-
ease and traits which give us new insights into the di-
verse causes of cirrhosis.
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and subjects with that character were included as having cirrhosis 
with the following exceptions: (a) if the word ‘without’ or ‘no’ ap-
peared in the same sentence as ‘cirrho’, subjects were considered 
controls; (b) if the words ‘primary biliary cirrhosis’ appeared in a 
sentence, that sentence was ignored for text search purposes to 
avoid falsely identifying individuals with primary biliary cholan-
gitis as having cirrhosis and (c) if the words ‘evaluate’, ‘assess’ or 
‘rule out’ appeared in a sentence with ‘cirrho’, that sentence was 
ignored for text search purposes. All subjects without ICD-9/-10 
diagnosis code or positive text search were included as controls. 
A gastroenterologist (VLC) manually reviewed 200 randomly se-
lected text strings and identified no false-positive cirrhosis diag-
noses. Only SNPs with a minor allele count >6 in MGI for cirrhosis 
were tested for replication as the others were underpowered to 
see an effect. Only lead SNPs were included for replication.
Association analyses in stage 1 and 2 were performed using Scalable 
and Accurate Implementation of GEneralized mixed model, which sub-
stantially reduces p value inflation otherwise seen in GWAS for rare 
traits,21 with a logistic mixed model and the saddlepoint approximation. 
Covariates included in this analysis were age, age,2 sex and principal 
components 1-10 to account for ethnic background. We used only a 
minimal number of covariates to maximize power and to avoid adjusting 
for potential mediators such as body mass index or diabetes mellitus.
Stage 3 analysis included replicating SNPs as well as SNPs that 
have been previously reported to associate with cirrhosis in subpop-
ulations, as described in the introduction (Table S1).5,8,9,12-16,22-32 
As above, we included only SNPs with minor allele count >6 in the 
European populations of UKBB and MGI, which corresponded to 
minor allele frequency >0.006. For stage 3 SNPs, a cut-off of P < .05 
in either UKBB or MGI was used because there was prior knowledge 
of their role in liver disease and fibrosis.
All SNP coordinates were reported based on GRCh38.p12 or, if 
updated during the most recent patch, p13.
C statistics for prediction of cirrhosis were calculated first using 
a minimal model that included only age, age,2 sex and principal com-
ponents 1-10, then adding cirrhosis-increasing SNPs. These were 
computed separately in MGI and UKBB.
2.4 | Phenome-wide association study (PheWAS)
To assess the effects of SNPs on other human diagnoses and dis-
eases, we carried out PheWAS on all SNPs identified in stage 1-3 
analysis based on published data on 778 traits (http://genea tlas.
roslin.ed.ac.uk/phewa s/).17 For statistical significance of individ-
ual traits, a Bonferroni-corrected P value cut-off of 0.05 corrected 
F I G U R E  1   Study design
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for eight SNPs and 778 traits was used (P = 9.2 × 10−6; Z = 4.46). 
Significant diagnoses with associated ICD-10 codes or blood cell 
traits are shown. Hierarchical clustering on SNPs (but not traits) 
was performed using the gplot package using default settings. We 
conducted sensitivity analysis where we adjusted for cirrhosis sta-
tus the associations between each significant SNP-trait pair repli-
cating the models of the original PheWAS.17 We conducted among 
unrelated Caucasian individuals in UKBB logistic regression (for 
binary traits) or linear regression (for quantitative traits) with each 
trait as the primary dependent variable and each SNP as the pri-
mary independent variable. Covariates were age, age,2 sex, prin-
cipal components 1-20, genotyping batch and assessment centre, 
with or without adjustment for cirrhosis status. A Z score change 
of >1.96 (corresponding to P < .05 for a difference between the 
associations) between the cirrhosis-adjusted and -unadjusted 
analyses was used as a cut-off for significant effect modification 
by cirrhosis.
We also tested the effect of all stage 1-3 SNPs on mean alanine 
aminotransferase (ALT), alkaline phosphatase (AP) and AST to plate-
let ratio index (APRI) in MGI. ALT, AP and APRI were inverse-nor-
mally transformed and linear regression was performed for SNP 
effects, adjusted for age, age,2 sex and principal components 1-10. 
As above, we used a minimal set of covariates to avoid including me-
diators and to maximize statistical power.
2.5 | Metabolomic analysis
All SNPs identified in stage 1-3 analysis were tested for association 
with serum metabolites from previously published data.33 In brief, 
the authors performed genotyping and high-throughput nuclear 
magnetic resonance serum/plasma metabolomics on 14 datasets 
from 10 European cohorts. Data on 123 metabolites in up to 24 925 
individuals were included. Because the traits were highly cross-cor-
related (Figure S1), data are only shown for certain representative 
metabolites. A Bonferroni-corrected significance cut-off of 0.05 cor-
rected for eight SNPs and 123 metabolites was used (P = 2.5 × 10-5; 
Z = 4.05).
2.6 | Cross-trait analyses
All SNPs identified in stage 1-3 analysis were tested for association 
with metabolic traits using publicly available data from nine GWAS. 
These studies were as follows: CARDIoGRAM-CAD34 (coronary ar-
tery disease; http://www.cardi ogram plusc 4d.org/data-downl oads), 
DIAGRAM35 (type 2 diabetes; http://diagr am-conso rtium.org/downl 
oads.html), GCLC36 (high- and low-density lipoproteins, total cho-
lesterol, triglycerides; http://csg.sph.umich.edu/abeca sis/publi c/
lipid s2013/ ), GIANT37 (body mass index, height, waist-to-hip ratio, 
waist-to-hip ratio adjusted for body mass index; https ://www.broad 
insti tute.org/colla borat ion/giant/ index.php/GIANT_conso rtium_
data_files ), MAGIC38 (fasting insulin and glucose levels; http://www.
magic inves tigat ors.org/downl oads/), a leptin GWAS39 and a body 
fat percentage GWAS40 (https ://walke r05.u.hpc.mssm.edu for the 
last two). There is no adequately powered GWAS for blood pres-
sure with full publicly available data, so GWAS for systolic and dias-
tolic blood pressure were performed on individuals of white-British 
ancestry in UKBB using Scalable and Accurate Implementation of 
GEneralized mixed model and a linear mixed model.21 In addition, 
data from the GOLD consortium were used to determine the effect 
of these SNPs on hepatic steatosis, as measured by lower liver at-
tenuation on computed tomography relative to a ‘phantom’ control.9 
Heat maps and clustering were performed using Z scores of SNP-
trait associations. Only traits that were associated with at least one 
SNP at nominal significance (P < .05) were included in the heat map, 
so only seven GWAS were included. For statistical significance, a 
Bonferroni-adjusted p value cut-off of 0.05 divided by seven SNPs 
(one of the identified SNPs and its proxies were not available in any 
of the public GWAS data) and 17 traits (P = 4.2 × 10−4; Z = 3.52) was 
used.
2.7 | Tissue and pathway analyses
Analysis of pathway and tissue enrichment was performed using 
FUMA-GWAS as previously reported.41 The background gene set 
used was ‘all’. Tissue enrichment was based on Genome-Tissue 
Expression Project version 6 and pathway enrichment on Reactome 
and Gene Ontology biological process terms.
3  | RESULTS
3.1 | Genome-wide association study
We carried out genome-wide association analyses for ~70 million 
imputed SNPs with cirrhosis (n = 1088 cases identified using ICD-10 
codes vs. 407 873 controls without this diagnosis) in UKBB control-
ling for age, gender, and the first 10 principal components using a 
Scalable and Accurate Implementation of GEneralized logistic mixed 
model. There was no significant inflation of the association statistic 
with a lambda of 0.97 (Figure 2A). Two SNPs associated with cirrho-
sis at genome-wide significance levels (P < 5 × 10−8) and an additional 
12 had a suggestive association with P < 5 × 10−6 (Figure 2B, Table 1, 
Table S2). We tested SNPs with suggestive association with cirrhosis 
(P < 5 × 10−6) in UKBB with cirrhosis in MGI (n = 875 cases based 
on ICD-10 codes and text search, vs. 31 221 controls). Only eight 
SNPs were common enough to have enough power to be evaluated 
for association with cirrhosis in MGI (Table 1, Table S2). Of these, 
two were significantly associated with increased cirrhosis preva-
lence (P < .05) in MGI: rs738408-T (PNPLA3 exon) and rs80215559-C 
(SLC17A2 intron) (Table 1). Of note, rs80215559 is in complete link-
age with rs1800562 (r2 = 1.0 in CEU/GBR), which is also associated 
with cirrhosis at genome-wide significance levels (P = 3.3 × 10−8) 
and corresponds to the HFE C282Y mutation, the primary cause of 
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hereditary hemochromatosis.16 Conditional analysis of the effect of 
rs80215559 on cirrhosis conditional on rs1800562 eliminated its as-
sociation with cirrhosis (odds ratio 1.61 [95% CI 1.33-1.84] to 1.00 
[95% CI 1.00-1.00]), suggesting that its effect is because of the HFE 
C282Y mutation.
3.2 | Candidate variant analysis
We also examined the effects of SNPs that have previously been 
associated with cirrhosis owing to any cause of liver disease (Table 
S1). Rs738409-G (PNPLA3), rs1800562-G (HFE), rs28929474-C 
F I G U R E  2   Quantile-quantile and Manhattan plots for GWAS of cirrhosis in UK BioBank. A, Quantile-quantile plot. B, Manhattan plot. 
GWAS, genome-wide association study
TA B L E  1   Loci that associate with cirrhosis in UK BioBank or Michigan Genomics Initiative
CHR:POS Variant Gene Ref/Alt
UK BioBank Michigan Genomics Initiative
EAF Beta SE P value EAF Beta SE P value
22:43928850 rs738408 PNPLA3 
(m)
C/T 0.216 0.472 0.055 6.73E-18 0.233 0.269 0.058 3.54E-06
6:25917997 rs80215559 SLC17A2 
(i), HFE (b)
T/C 0.077 0.477 0.083 9.13E-09 0.059 0.280 0.106 8.39E-03
22:43928847 rs738409 PNPLA3 
(m)
C/G 0.216 0.470 0.055 9.58E-18 0.233 0.269 0.058 3.56E-06
6:26092913 rs1800562 HFE (m) G/A 0.078 0.454 0.082 3.30E-08 0.062 0.300 0.102 3.09E-03
19:19268740 rs58542926 TM6SF2 
(m)
C/T 0.076 0.378 0.084 6.01E-06 0.075 0.086 0.093 3.54E-01
14:94378610 rs28929474 SERPINA1 
(m)
C/T 0.020 0.727 0.162 7.35E-06 0.018 0.456 0.180 1.11E-02
4:87310241 rs72613567 HSD17B13 
(s)
-/A 0.721 0.178 0.048 2.30E-04 NA
19:54173307 rs626283 MBOAT7 
(d)
G/C 0.440 0.121 0.044 5.48E-03 0.433 0.031 0.050 5.31E-01
2:191099907 rs7574865 STAT4 (i) T/G 0.224 0.117 0.052 2.38E-02 0.224 0.077 0.059 1.87E-01
19:39248147 rs12979860 IFNL4 (i) T/C 0.299 0.081 0.047 8.40E-02 0.317 0.115 0.053 3.05E-02
Note: UK BioBank had 1088 cases and 407 874 controls, and Michigan Genomics Initiative had 875 cases and 30 346 controls. Additional variants are 
shown in Table S1.
Abbreviations: (b), biologically relevant gene; (i), intron; (m), missense mutation; (s), splice variant; Alt, alternate allele; CHR: POS, chromosome: 
position; EAF, effect allele frequency; NA Not available; Ref, reference allele; SE, standard error.
Bold value indicates that the association is statistically significant.
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(SERPINA1), rs58542926-C (TM6SF2), rs6834314-A and rs72613567-
(no insertion) (HSD17B13), rs641738-T and rs626283-G (MBOAT7), 
and rs7574865-T (STAT4) associated with cirrhosis in UKBB, 
and rs738409-G (PNPLA3), rs1800562-G (HFE), rs28929474-C 
(SERPINA1), rs6834314-A (HSD17B13), and rs12979860-T (IFNL4) 
associated with cirrhosis in MGI (Table 1). The allele for each 
gene with the lowest p value in UKBB was included in subsequent 
analysis, except in the case of rs738409, which we chose in lieu of 
rs738408 as rs738409 is in high LD (R2 = 1) and corresponds to the 
causal variant.42
The C statistics for a minimal model and a model including all 
eight cirrhosis-increasing SNPs were, respectively, 0.63 and 0.67 in 
UKBB and 0.61 and 0.63 in MGI.
3.3 | Effects on liver enzymes
We investigated whether these SNPs had effects on markers 
of liver injury such as serum ALT, a marker of hepatocellular in-
jury; AP, a marker of cholestasis/infiltrative disease; and APRI, a 
non-invasive marker of liver fibrosis.43 Rs6834314 was used as 
a proxy for rs72613567 (R2 = 0.94), as the latter was not available 
in MGI. Both rs738409-G (PNPLA3) and rs8021559-C (HFE) as-
sociated with increased APRI, consistent with a role in worsening 
fibrosis (P = 1.75 × 10−17 and 7.41 × 10−3, respectively) (Table 2). 
In addition, rs738409-G (PNPLA3) associated with increased ALT 
(P = 1.42 × 10−14), but not AP, while rs80215559-C (HFE) associated 
with increased AP (P = 8.46 × 10−3) but not ALT (Table 2). PNPLA3, 
HFE, SERPINA1, MBOAT7 and HSD17B13 variants increase AP while 
TM6SF2 decreased AP (P < .05 for all). PNPLA3, HFE, TM6SF2, 
HSD17B13 all increased ALT (P < .05 for all). PNPLA3, HFE, SERPINA1 
and HSD17B13 all associated with increased APRI (P < .05 for all). 
STAT4 and IFNL4 did not associate with abnormal liver enzymes in 
MGI.
3.4 | Tissue/pathway analyses and PheWAS
The genes implicated by the variants were upregulated in liver 
(Figure S2A).41 Gene Ontology analysis showed that these same 
genes were enriched for effects on pathways related to inflamma-
tion, lipid synthesis and protein complex synthesis (Figure S2B). 
However, these analyses were based on previously annotated 
pathways, and we sought to use a more unbiased approach to de-
termine whether cirrhosis-associated SNPs had effects on other 
human diseases and traits using PheWAS analysis of diagnoses/
traits in UKBB (Table S3). Nearly all traits were either ICD-10 di-
agnoses (Figure 3A) or blood cell traits (Figure 3B). We replicated 
known disease processes: rs1800562-A (HFE) associated with nu-
merous red blood cell-related traits and increased arthroses and 
skin infections and rs2892947-T (SERPINA1) associated with in-
creased emphysema. On PheWAS, PNPLA3 and TM6SF2 variants 
clustered together owing to effect on various liver diseases as well 
as, unexpectedly, decreased neutrophil count, haemoglobin traits 
and platelet traits. TM6SF2 and SERPINA1 variants had distinct ef-
fects on anthropometric traits: the former decreased peripheral 
fat while the latter increased it (Table S3). Multiple variants as-
sociated with blood cell traits; some of the unique associations 
included HSD17B13 and basophil count/percentage, STAT4 with 
eosinophil count/percentage, TM6SF2 with neutrophil count and 
PNPLA3 with leukopenia (Figure 3B).
Cirrhosis is itself associated with numerous physiological al-
terations including in lipid profiles, platelet count and red blood 
cell count. Thus, as sensitivity analysis, we performed a PheWAS 
in UKBB adjusted for cirrhosis status. For continuous traits, none 
of the Z scores changed significantly (Z score change >1.96) after 
adjustment for cirrhosis (Table S4). For binary traits, associations 
between the SNPs and several liver-related traits (including oe-
sophageal varices and liver fibrosis/cirrhosis itself) changed in sig-
nificance. However, no associations between SNPs and non-liver 
binary traits changed in significance; indeed, other than liver-related 
traits, no Z scores changed by >1 (Table S4). This analysis indicates 
that the associations between cirrhosis-increasing SNPs and non-
liver diseases/traits are not due solely to the effect of these SNPs 
on cirrhosis.
3.5 | Metabolic traits and metabolomics
We also characterized whether cirrhosis-associated variants asso-
ciated with any of 19 different metabolic phenotypes (Methods; 
Table S5; Figure 3C). Owing to missing data, we used rs10401969 
as a proxy for rs58542926 (TM6SF2; R2 = 0.95) and rs6834314 for 
rs72613567 (HSD17B13; R2 = 0.94); there were no acceptable link-
age disequilibrium proxies (R2 > 0.5) for rs28929474 (SERPINA1) 
in European populations with available data in the GWASs, so 
this variant was not included in this analysis. Several variants 
with known metabolic effects clustered together: rs738409-G 
(PNPLA3) and rs5854292-T (TM6SF2) associated with decreased 
liver attenuation (increased liver fat) and altered lipid profiles. 
We also identified a separate cluster of variants which had not 
been thought to mediate liver disease through metabolic altera-
tions, with effect on numerous metabolic traits. For example, 
rs1800562-A (HFE) decreased low-density lipoprotein and total 
cholesterol, and increased height and blood pressure. Rs626283-C 
(MBOAT7) decreased serum triglycerides.
We finally determined the effect of cirrhosis-associated vari-
ants on 123 metabolites based on previously published data 
(Figure 3D, Table S6).33 Because the metabolites were highly 
cross-correlated (Figure S1), we performed hierarchical clustering 
and with metabolite clusters shown in Table S6. Consistent with 
our previous report, the cirrhosis promoting allele rs58542926-T 
(TM6SF2) associated with decreased concentration of very 
low-density, intermediate- and high-density lipoproteins.44 The 
cirrhosis promoting allele rs2892474-T (SERPINA1) also associ-
ated with decreased glycoproteins with several other suggestive 
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associations. MBOAT7 associated with fewer CH2 groups in fatty 
acids.
4  | DISCUSSION
In this study, we identified common and low-frequency genetic vari-
ants that associate with population-based cirrhosis. PheWAS and 
metabolomic analysis identified distinct metabolic effects of cirrho-
sis associated variants suggesting that liver disease caused by many 
mechanisms can lead to cirrhosis.
Previously, rare diseases such as cirrhosis, which has an esti-
mated prevalence of 1%, have been difficult to study at a popu-
lation level.2 With the use of large cohorts of densely genotyped 
and well-characterized individuals, here we show that even pre-
viously considered rare liver diseases such as alpha-1 anti-tryp-
sin deficiency and hereditary hemochromatosis contribute to 
population-based cirrhosis. Furthermore, using biobank PheWAS 
analysis, we verified known genetic pleiotropisms associated with 
cirrhosis promoting variants including dyslipidaemia, diabetes and 
body fat composition for six identified variants.45-47 Others have 
reported associations between HFE C282Y and arthritis, diabe-
tes, chronic pain and brain iron accumulation,48-50 and SERPINA1 
variants and hepatitis and fibrosis.51-54 Another recent study 
identified a SNP in MARC1 associated with cirrhosis, which was 
also associated with cirrhosis in UKBB (P = .047); differences in 
strengths of associations are likely due to differences in statisti-
cal power and definitions of cirrhosis.55 However, we also identi-
fied previously unreported associations such as increased body 
fat with SERPINA1, increased basophil count with HSD17B13, 
increased neutrophil count despite decreased overall leukocyte 
count with PNPLA3, and multiple sclerosis with HFE that might 
give new insights into disease pathophysiology caused by variants 
at these loci.
Most cirrhosis-increasing variants increased AP, suggesting a 
common pathway towards liver cholestasis with cirrhosis. TM6SF2 
was a strong notable exception where the cirrhosis-promoting al-
lele decreased AP. The mechanism of that is not clear but one in-
triguing possibility is that cholesterol (which cannot be excreted in 
very low-density lipoprotein in individuals with TM6SF2 variants56) 
is shunted to bile synthesis which increases farsenoid × receptor ag-
onism and lowers AP.57 Notably, PNPLA3 and HSD17B13 variants did 
not associate with AP but did increase ALT, suggesting hepatocellu-
lar toxicity and potentially distinct disease mechanisms. Some vari-
ants (in PNPLA3, HFE, SERPINA1 and HSD17B13) also associated with 
AST-to-platelet ratio index, suggesting that we may be able to use 
non-invasive scores to find more variants that associate with cirrho-
sis in populations where we do not have diagnoses or direct imaging 
or pathology verification of the disease.
Genetic variants implicated genes that were enriched for expres-
sion in liver which suggests likely tissue autonomous effect of these 
variants. HFE and SERPINA1 were part of acute phase and inflamma-
tory response pathways but these genes as well as all the other ones 
(PNPLA3, TM6SF2, HSD17B13, and MBOAT7) either were part of 
lipid metabolism affecting pathways or affected serum lipids in our 
metabolomics analyses. While cirrhosis itself alters lipid profiles,58 
there was a low prevalence of cirrhosis in both cohorts, so these 
lipid changes are unlikely to be driven by cirrhosis alone. Another 
interesting possibility is that disruptions in lipid signalling represent 
a final common pathway to cirrhosis. PNPLA3 and HSD17B13, for ex-
ample, may alter metabolism of vitamin A to retinoic acid to effect 
cirrhosis and is known to promote stellate cell activation and liver 
fibrosis.8,59 Whether the effect of other variants will ultimately con-
verge on this as a mechanism to all fibrosis remains to be determined. 
The biochemical effects of the variants that promote liver damage, 
however, are diverse and thus it is not likely that one solution to 
eliminating liver damage will be possible even if the final common 
fibrotic pathway is curbed.
TA B L E  2   Association between liver enzymes and cirrhosis-affecting variants in Michigan Genomics Initiative
Variant Gene
Alanine aminotransferase Alkaline phosphatase AST-to-platelet ratio index
Beta SE P value Beta SE P value Beta SE P value
rs738409 PNPLA3 (m) 0.091 0.012 1.42E-14 0.009 0.012 4.39E-01 0.102 0.012 1.75E-17
rs80215559 SLC17A2 (i), 
HFE (b)
0.020 0.022 3.55E-01 0.058 0.022 8.46E-03 0.059 0.022 7.41E-03
rs1800562 HFE (m) 0.268 0.037 3.93E-13 0.059 0.021 4.60E-03 0.063 0.021 2.60E-03
rs28929474 SERPINA1 (m) 0.268 0.037 3.93E-13 0.264 0.037 9.67E-13 0.214 0.037 8.82E-09
rs58542926 TM6SF2 (m) 0.085 0.019 8.00E-06 −0.103 0.019 6.28E-08 0.027 0.019 1.54E-01
rs626283 MBOAT7 (d) 0.009 0.010 3.92E-01 0.026 0.010 1.27E-02 0.004 0.010 6.70E-01
rs6834314 HSD17B13(u) 0.039 0.011 1.11E-02 −0.014 0.011 2.15E-01 0.036 0.011 1.26E-03
rs7574865 STAT4 (i) 0.013 0.012 2.86E-01 −0.002 0.012 8.96E-01 0.019 0.012 1.03E-01
rs12979860 IFNL4 (i) 0.004 0.011 6.85E-01 0.009 0.011 4.15E-01 0.001 0.011 9.14E-01
Note: N = 19 598 for alanine aminotransferase, 19 493 for alkaline phosphatase, and 19 269 for aspartate aminotransferase-to-platelet ratio index.
Abbreviations: (b), biologically relevant gene; (d), downstream gene; (i), intron; (m), missense mutation.
Bold value indicates that the association is statistically significant.
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Clustering of genes differs based on whether previously anno-
tated or agnostic methods are used. When previously annotated 
pathways such as Reactome are used, PNPLA3, TM6SF2, HSD17B13 
and MBOAT7 cluster because they affect lipid traits, which is dis-
tinct from HFE and SERPINA1 which more affect acute phase and 
inflammatory responses. Using more agnostic approaches, we show 
here that MBOAT7 also affects inflammation-related traits including 
neutrophil count and (at nominal significance) ankylosing spondyli-
tis, peritonitis and appendicitis. The effect of MBOAT7 on the im-
mune system has been suggested before – it is expressed at high 
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levels in immune cells and MBOAT7 variants are associated with in-
creased inflammation with chronic hepatitis C infection60 – but here 
we demonstrate this at the population level. Conversely, HFE and 
SERPINA1 affect serum lipids and SERPINA1 also affects body fat 
composition and weight.
Cirrhosis-promoting variants protect against development of 
other human disease suggesting that simply reversing their effects 
may not be universally beneficial. For example, cirrhosis-causing 
variants decrease coronary artery disease/ischaemic heart dis-
ease (TM6SF2, SERPINA1),61,62 diabetes (TM6SF2), total cholesterol 
(PNPLA3, HFE, TM6SF2) and triglycerides (MBOAT7, HSD17B13, 
TM6SF2). These findings imply that medications may need to be per-
sonalized based on individual risk factors and environmental expo-
sures to be able to reverse fibrosis while maintaining an adequate 
cardiovascular safety profile.
Non-alcoholic fatty liver disease is a major cause of cirrhosis in 
the population. Notably, though, genes that predispose to hepatic 
steatosis do not necessarily increase risk of fibrosis. We previously 
showed that variants in/near GCKR and LYPLAL1 increase non-alco-
holic steatohepatitis/fibrosis,9 but in this study we did not find that 
they increased cirrhosis in the population. This discrepancy could be 
in part because they had a weaker effect on fibrosis than variants 
in TM6SF2, PNPLA3 or HSD17B13. Also, GCKR and LYPLAL1 variants 
may primarily affect steatosis or inflammation and not fibrosis: in our 
previous study, most individuals with non-alcoholic steatohepatitis 
also had fibrosis, so we were not able to distinguish between effects 
on inflammation alone vs. fibrosis. It will be critical to distinguish be-
tween steatohepatitis and fibrosis in future studies investigating the 
effect of genetics on outcomes in NAFLD.
Limitations of our study include that it included only individu-
als of European ancestry and may not have identified cirrhosis-in-
creasing alleles that may be prevalent in only other ancestry groups. 
Interestingly, though, we replicated variants previously associated 
with cirrhosis in Asian populations, suggesting that many variants 
will have effects across populations. Furthermore, the UKBB analy-
ses rely on ICD codes, and while the codes we used for cirrhosis are 
specific, they are not sensitive, which may reduce overall sensitivity 
for identifying cirrhosis-altering variants.63 This limitation may be 
why only two SNPs were identified on GWAS, whereas the rest were 
identified based on candidate variant analysis. Finally, rare diseases 
such as primary biliary cholangitis are under-represented in the gen-
eral population, so genetic effects that require particular exposures 
to develop cirrhosis only in some but not all populations may not be 
detected.64 On a related note, we lacked adequate power to sub-
classify patients with cirrhosis based on disease aetiology. Strengths 
include that this is the largest GWAS for cirrhosis to date.
We demonstrate that eight loci promote cirrhosis in popula-
tion-based data and define their effects on human diseases and 
traits including many novel pleiotropic effects. We identified pre-
viously unrecognized metabolic and immune effects of several of 
these SNPs and defined novel gene clustering. This work gives new 
insights into the pathophysiology of cirrhosis.
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